Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Ariane L. Herrick. (2017) Therapeutic implications from the pathogenesis of Raynaud’s phenomenon. Expert Review of Clinical Immunology 13:7, pages 723-735.
Read now
Read now
J. D. Pauling, V. B. O’Donnell & N. J. Mchugh. (2013) The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis. Platelets 24:7, pages 503-515.
Read now
Read now
S Ziegler, M Brunner, E Eigenbauer & E Minar. (2003) Long‐term outcome of primary Raynaud's phenomenon and its conversion to connective tissue disease: a 12‐year retrospective patient analysis. Scandinavian Journal of Rheumatology 32:6, pages 343-347.
Read now
Read now
Ferdinando Silveri, Rossella De Angelis, Andreina Poggi, Stefania Muti, Giuseppe Bonapace, Franco Argentati, Claudio Cervini. (2001) Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scandinavian Journal of Rheumatology 30:5, pages 290-296.
Read now
Read now
M. Bashar Kahalefp & E. Carwile Leroy. (1999) Autoimmunity and Vascular Involvement in Systemic Sclerosis (SSc). Autoimmunity 31:3, pages 195-214.
Read now
Read now
Meilien Ho, Jill Belch. (1998) Raynaud's Phenomenon: State of the Art 1998: EDITORIAL REVIEW. Scandinavian Journal of Rheumatology 27:5, pages 319-322.
Read now
Read now
M. Bashar Kahaleh. (1995) The Vascular Endothelium in Scleroderma. International Reviews of Immunology 12:2-4, pages 227-245.
Read now
Read now
Articles from other publishers (21)
Nehme El-Hachem, Manal M. Fardoun, Hasan Slika, Elias Baydoun & Ali H. Eid. (2021) Repurposing Cilostazol for Raynaud's Phenomenon. Current Medicinal Chemistry 28:12, pages 2409-2417.
Crossref
Crossref
Joanna Żuk, Agnieszka Snarska-Drygalska, Krzysztof Piotr Malinowski, Elżbieta Papuga-Szela, Joanna Natorska & Anetta Undas. (2019) Unfavourably altered plasma clot properties in patients with primary Raynaud’s phenomenon: association with venous thromboembolism. Journal of Thrombosis and Thrombolysis 47:2, pages 248-254.
Crossref
Crossref
Keren Bakal, Mauricio Danckers, Joshua L. Denson & Harald Sauthoff. (2015) Therapeutic Hypothermia After Cardiac Arrest in a Patient With Systemic Sclerosis and Raynaud Phenomenon. Chest 147:2, pages e27-e30.
Crossref
Crossref
Michael W. Neumeister. (2015) The Role of Botulinum Toxin in Vasospastic Disorders of the Hand. Hand Clinics 31:1, pages 23-37.
Crossref
Crossref
Ariane L. Herrick. 2015. Raynaud’s Phenomenon. Raynaud’s Phenomenon
81
93
.
L. Polidoro, R. Barnabei, P. Giorgini, L. Petrazzi, C. Ferri & G. Properzi. (2012) Platelet activation in patients with the Raynaud phenomenon. Internal Medicine Journal 42:5, pages 531-535.
Crossref
Crossref
Mo Yin Mok, Chak Sing Lau, Sonny Sau Hin Chiu, Annette Wai Kwan Tso, Yi Lo, Lawrence Siu Chun Law, Ka Fung Mak, Woon Sing Wong, Peh Lan Khong & Karen Siu Ling Lam. (2011) Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis & Rheumatism 63:5, pages 1387-1395.
Crossref
Crossref
Zsuzsanna H McMahan & Fredrick M Wigley. (2010) Raynaud’s phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management. International Journal of Clinical Rheumatology 5:3, pages 355-370.
Crossref
Crossref
Elena Schiopu, Ann J. Impens & Kristine Phillips. (2010) Digital Ischemia in Scleroderma Spectrum of Diseases. International Journal of Rheumatology 2010, pages 1-8.
Crossref
Crossref
Stefano Alivernini, Maria De Santis, Barbara Tolusso, Alice Mannocci, Silvia Laura Bosello, Giusy Peluso, Michela Pinnelli, Graziella D'Antona, Giuseppe LaTorre & Gianfranco Ferraccioli. (2009) Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing. Journal of the American Academy of Dermatology 60:3, pages 426-435.
Crossref
Crossref
Richard Bakst, Joseph F. Merola, Andrew G. FranksJr.Jr. & Miguel Sanchez. (2008) Raynaud's phenomenon: Pathogenesis and management. Journal of the American Academy of Dermatology 59:4, pages 633-653.
Crossref
Crossref
Emma Beltrán Catalán, José A. Román Ivorra, Juanjo Alegre Sancho, Inmaculada Chalmeta Vedejo, Nagore Fernández-Llanio Comella & José Ivorra Cortés. (2008) Úlceras digitales en la esclerosis sistémica. Seminarios de la Fundación Española de Reumatología 9:1, pages 3-25.
Crossref
Crossref
Gülsüm Emel Pamuk, Burhan Turgut, Ömer Nuri Pamuk, Özden Vural, Muzaffer Demir & Necati Çakr. (2007) Increased circulating platelet–leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study. Blood Coagulation & Fibrinolysis 18:4, pages 297-302.
Crossref
Crossref
Laura K. Hummers. (2006) Microvascular damage in systemic sclerosis: Detection and monitoring with biomarkers. Current Rheumatology Reports 8:2, pages 131-137.
Crossref
Crossref
Lorinda Chung & David Fiorentino. (2006) Digital ulcers in patients with systemic sclerosis. Autoimmunity Reviews 5:2, pages 125-128.
Crossref
Crossref
A. L. Herrick. (2005) Pathogenesis of Raynaud's phenomenon. Rheumatology 44:5, pages 587-596.
Crossref
Crossref
Laura K. Hummers & Fredrick M. Wigley. (2003) Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheumatic Disease Clinics of North America 29:2, pages 293-313.
Crossref
Crossref
Carol Black & Christopher Denton. 2001. Vascular Manifestations of Systemic Autoimmune Diseases. Vascular Manifestations of Systemic Autoimmune Diseases.
H.R. Hellstrom. (1999) New evidence for the spasm-of-resistance-vessel concept of ischemic diseases. Medical Hypotheses 53:3, pages 200-209.
Crossref
Crossref
F Khan. (2016) Vascular Abnormalities in Raynaud's Phenomenon. Scottish Medical Journal 44:1, pages 4-6.
Crossref
Crossref
Marco Matucci-Cerinic, Alberto Pignone, Maria Biagini & Torello Lotti. (1994) Markers of disease activity in systemic sclerosis. Clinics in Dermatology 12:2, pages 291-297.
Crossref
Crossref